Effect of LMWH on Neonatal Outcomes in Isolated Oligohydramnios

The pregnant women who meet the study requirements will be included in the study. They will be randomly assigned to receive either the usual treatment or the usual treatment along with an additional medicine. The usual treatment will include fluids given through a vein, rest while lying on the left side, and a low-dose aspirin tablet (75 mg once daily) from the 22nd to the 34th week of pregnancy. Women will also receive 1,000 ml of 5% dextrose fluid daily through a vein, from the time low amniotic fluid is diagnosed until the 36th week of pregnancy. Some women will also receive an additional injection of a blood-thinning medicine called low-molecular-weight heparin (LMWH), at a dose of 40 mg under the skin, from the 22nd to the 36th week of pregnancy. All participants will undergo weekly ultrasound examinations to measure the fluid surrounding the baby and assess blood flow through the umbilical cord. The study will record the number of babies born before 37 weeks of pregnancy, the babies' birth weights, and the number of babies born alive.

Inclusion Criteria: 1. Pregnant patients at in second and third trimester. 2. Isolated oligohydramnios with AFI \< 8 cm 3. Singelton pregnancy 4. Intact membranes Exclusion Criteria: 1. Hypertension 2. Diabetes 3. Fetal abnormalities 4. Who were already on any treatment for oligohydramnios 5. Patient having premature pre term rupture of membranes